title: [Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
abstract: OBJECTIVE
  Hepaticarterial infusional(HAI)5-FU chemotherapy, which involves the use of interventional radiology technique, has matured technically in Japan in the 1990's. The antitumor effect of 5-FU is enhanced by combination with leucovorin. This study was performed to evaluate the efficacy and toxicity of HAI 5-FU and leucovorin chemotherapy for patients with unresectable liver metastases from colorectal cancer.
  
  
  METHODS
  Treatment was given to 20 patients with unresectable liver metastases from colorectal cancer. The chemotherapy regimen consisted of weekly HAI of 5-FU(1,000 mg/body)and leucovorin(250 mg/body)over five hours. The survival and response rates to the therapy were assessed according to RECIST. Hematologic and non-hematologic toxicity was assessed according to CTCAE v3.0.
  
  
  RESULTS
  Combined HAI 5-FU and leucovorin therapy was carried out an average of 27 times. The response rate for liver tumors was 75%, and the median survival time was 22 months. The applied regimen caused only mild adverse events. There was no evidence of myelosuppression except for platelet decrease(grade 3)in a patient with chronic renal failure.
  
  
  CONCLUSIONS
  This HAI approach using 5-FU and leucovorin was effective and the therapy for unresectable liver metastases from colorectal cancer was tolerated well. Therefore the HAI approach should be reconsidered as an effective therapy against this disease in Japan.
authors.affiliation: Dept. of Surgery, Division of Gastroenterology, Kawasaki Medical School.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Yamashita
authors.forename: Atsushi
authors.initials: A
authors.lastname: Urakami
authors.forename: Hisako
authors.initials: H
authors.lastname: Kubota
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Nagatsuka
authors.forename: Haruaki
authors.initials: H
authors.lastname: Murakami
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Kawabe
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashida
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Mikami
authors.forename: Masaharu
authors.initials: M
authors.lastname: Ikeda
authors.forename: Michihisa
authors.initials: M
authors.lastname: Fuchimoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Oka
authors.forename: Hideo
authors.initials: H
authors.lastname: Okumura
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Iki
authors.forename: Hideo
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Shigeki
authors.initials: S
authors.lastname: Imai
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Hirai
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Tsunoda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
chemical_list: D002955:Leucovorin; D005472:Fluorouracil